zevesin 10 mg
zentiva a.s., slovensko - solifenacín - 73 - spasmolytica
rosuvastatin mylan 5 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 10 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 20 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 40 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
tiaprid pmcs 100 mg
pro.med.cs praha a.s., Česká republika - tiaprid - 68 - antipsychotica (neuroleptica)
azibiot neo 40 mg/ml prášok na perorálnu suspenziu
krka, d.d., novo mesto, slovinsko - azitromycín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
azibiot neo 20 mg/ml prášok na perorálnu suspenziu
krka, d.d., novo mesto, slovinsko - azitromycín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - iné antineoplastické látky - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatické nádory - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.